Polymorphisms in the XRCC1 gene are associated with treatment response to platinum chemotherapy in advanced non-small cell lung cancer patients based on meta-analysis

Genetics and Molecular Research

Volumn 13, Issue 2, 2014, Pages 3772-3786

  Li, L ^a   Wan, C ^a   Wen, F Q ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Chemotherapy; Gene polymorphism; Lung cancer; Meta analysis; Platinum; XRCC1

Indexed keywords

PLATINUM COMPLEX; XRCC1 PROTEIN; DNA BINDING PROTEIN; PLATINUM; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 1;

ADVANCED CANCER; ALLELE; ARTICLE; CANCER PATIENT; DISEASE ASSOCIATION; DNA POLYMORPHISM; DRUG RESPONSE; HETEROZYGOTE; HUMAN; LUNG NON SMALL CELL CANCER; XRCC1 GENE; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; META ANALYSIS; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ALLELES; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; DNA-BINDING PROTEINS; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; NEOPLASM STAGING; PLATINUM; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 84900839794     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2014.May.16.1     Document Type: Article

References (37)

1. Abdel-Rahman SZ and El-Zein RA (2000). The 399Gln polymorphism in the DNA repair gene XRCC1 modulates the genotoxic response induced in human lymphocytes by the tobacco-specific nitrosamine NNK. Cancer Lett. 159: 63-71.
2. Audebert M, Salles B and Calsou P (2004). Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J. Biol. Chem. 279: 55117-55126.
3. Bahl A and Falk S (2001). Meta-analysis of single agents in the chemotherapy of NSCLC: what do we want to know? Br. J. Cancer 84: 1143-1145.
4. Cheng HY, Chen BA, Sun XC, Sun N, et al. (2011). Relationship of single nucleotide polymorphisms and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Jiang Su Med. J. 37: 272-274.
5. Cui Z, Yin Z, Li X, Wu W, et al. (2012). Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis. BMC Cancer 12: 71.
6. Ding CL, Liu LH and Song H (2010). Polymorphism in XRCC1 and sensitivity to platin-based chemotherapy in advanced non-small cell lung cancer. China Pharm. 13: 1399-1401.
7. Duell EJ, Wiencke JK, Cheng TJ, Varkonyi A, et al. (2000). Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 21: 965-971.
8. Fan H, Huang XW, Zhang Q and Gao LL (2008). Relationship of XRCC1 and XPD gene polymorphisms with chemosensitivity to platinum-based chemotherapy in advanced non-small cell lung cancer. Pract. Geriatr. 22: 306-308.
9. Gao CM, Shi MQ, Wu JZ, Cao HX, et al. (2006). Polymorphisms in XRCC1 gene and sensitivity to gemcitabine/cisplatin chemotherapy in non small cell lung cancer. Practical. J. Cancer 21: 351-353.
10. Hoeijmakers JH (2001). Genome maintenance mechanisms for preventing cancer. Nature 411: 366-374.
11. Hong CY, Xu Q, Yue Z, Zhang Y, et al. (2009). Correlation of the sensitivity of NP chemotherapy in non-small lung cancer with DNA repair gene XRCC1 polymorphism. Ai. Zheng. 28: 1291-1297.
12. Horgan AM, Yang B, Azad AK, Amir E, et al. (2011). Pharmacogenetic and germline prognostic markers of lung cancer. J. Thorac. Oncol. 6: 296-304.
13. Hu JJ, Smith TR, Miller MS, Mohrenweiser HW, et al. (2001). Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. Carcinogenesis 22: 917-922.
14. Jemal A, Bray F, Center MM, Ferlay J, et al. (2011). Global cancer statistics. CA Cancer J. Clin. 61: 69-90.
15. Jin YW, Liu J and Wang ZH (2006). Prediction of XPD and XRCC1 gene polymorphisms in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy. Shandong Yi Yao 46: 42-43.
16. Kalikaki A, Kanaki M, Vassalou H, Souglakos J, et al. (2009). DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin. Lung Cancer 10: 118-123.
17. Li D, Zhou Q, Liu Y, Yang Y, et al. (2012). DNA repair gene polymorphism associated with sensitivity of lung cancer to therapy. Med. Oncol. 29: 1622-1628.
18. Lunn RM, Langlois RG, Hsieh LL, Thompson CL, et al. (1999). XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res. 59: 2557-2561.
19. Miller AB, Hoogstraten B, Staquet M and Winkler A (1981). Reporting results of cancer treatment. Cancer 47: 207-214.
20. Qian XP, Qiu LX, Yang Y, Jiang M, et al. (2010). Predictive value of base-excision repair gene polymorphisms in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy. Mod. Oncol. 18: 1303-1304.
21. Qiu LX, Qian XP, Liu BR, Hu WJ, et al. (2009). Predictive value of XRCC1 polymorphisms in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy. Mod. Oncol. 17: 263-265.
22. Shellard SA, Fichtinger-Schepman AM, Lazo JS and Hill BT (1993). Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines. Anticancer Drugs 4: 491-500.
23. Song DG, Liu J, Wang ZH and Song B (2007a). Predictive value of XRCC1 and XPD on platinum-based chemotherapy in advanced non-small cell lung cancer patients. Chin. J. Gerontol. 27: 1684-1686.
24. Song DG, Liu J, Wang ZH, Song B, et al. (2007b). Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer. Zhong Liu Fang Zhi Yan Jiu 34: 845-847.
25. Sun XC, Li F, Sun N, Qin SK, et al. (2009). Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung. Cancer. 65:230-236.
26. The Cochrane Collaborative Review Group on HIV Infection and AIDS (2009). Editorial Policy: Inclusion and Appraisal of Experimental and Non-Experimental (Observational) Studies. Available at [http://www.igh.org/Cochrane]. Accessed January 8, 2012.
27. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, et al. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92: 205-216.
28. Wang ZH, Miao XP, Tan W, Zhang XR, et al. (2004). Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer. Ai. Zheng. 23: 865-868.
29. Weaver DA, Crawford EL, Warner KA, Elkhairi F, et al. (2005). ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol. Cancer 4: 18.
30. Wells GA, Shea B, O'Connell D and Peterson J (2003). The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Available at [http://www.ohri.ca/programs/clinical epidemiology/oxford. htm]. Accessed January 8, 2012.
31. Whitehouse CJ, Taylor RM, Thistlethwaite A, Zhang H, et al. (2001). XRCC1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand break repair. Cell 104: 107-117.
32. Wood RD, Mitchell M, Sgouros J and Lindahl T (2001). Human DNA repair genes. Science 291: 1284-1289.
33. Xu C, Wang X, Zhang Y and Li L (2011). Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer. Zhongguo Fei. Ai. Za Zhi 14: 912-917.
34. Yao CY, Huang XE, Li C, Shen HB, et al. (2009). Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers. Asian Pac. J. Cancer Prev. 10: 859-864.
35. Yuan P, Miao XP, Zhang XM, Wang ZH, et al. (2006). XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 28: 196-199.
36. Zhou F, Lv HY, Liang J, Yu Z, et al. (2011a). Association of GSTPl and XRCCl genetic polymorphisms with the effects of platinum-based chemotherapy on advanced non-small cell lung cancer patients. Chin. Clin. Oncol. 16: 304-309.
37. Zhou F, Yu Z, Jiang T, Lv H, et al. (2011b). Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. Swiss. Med. Wkly. 141: w13275.